<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5239">
  <stage>Registered</stage>
  <submitdate>21/10/2015</submitdate>
  <approvaldate>21/10/2015</approvaldate>
  <nctid>NCT02598960</nctid>
  <trial_identification>
    <studytitle>An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.</studytitle>
    <scientifictitle>A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination With Nivolumab (BMS-936558, Anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2015-002505-11</secondaryid>
    <secondaryid>CA009-002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Solid Tumors</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BMS-986156
Treatment: drugs - Nivolumab

Experimental: Mono therapy - BMS-986156 (Dose Escalation) - BMS-986156 dose as specified

Experimental: Combination therapy - BMS-986156 + Nivolumab (Dose Escalation) - BMS-986156 + Nivolumab dose as specified

Experimental: Mono therapy - BMS-986156 (Dose Expansion) - BMS-986156 dose as specified

Experimental: Combination therapy - BMS-986156 + Nivolumab (Dose Expansion) - BMS-986156 + Nivolumab dose as specified


Treatment: drugs: BMS-986156


Treatment: drugs: Nivolumab


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety of BMS-986156 based on number of incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation and deaths in addition to clinical laboratory test abnormalities</outcome>
      <timepoint>Up to 30 days after the last dose of study drug</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Objective response rate (ORR) - ORR is defined as the proportion of all treated subjects whose best overall response is either a complete response (CR) or partial response (PR)</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression free survival rate (PFSR)</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response - Duration of response is defined as the time between the date of first response and the date of disease progression or death, whichever occurs first</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum observed concentration (Cmax) of BMS-986156</outcome>
      <timepoint>Day 1 to 56 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time of maximum observed concentration (Tmax) of BMS-986156</outcome>
      <timepoint>Day 1 to 56 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the concentration-time curve in one dosing interval (AUC [TAU]) of BMS-986156</outcome>
      <timepoint>Day 1 to 56 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T) of BMS-986156</outcome>
      <timepoint>Day 1 to 56 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Anti-drug antibody (ADA) response to BMS-986156</outcome>
      <timepoint>Day 1 to 56 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Anti-drug antibody response to BMS-986156 and Nivolumab</outcome>
      <timepoint>Day 1 to 56 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        

          -  For Dose Escalation:

               -  Subjects with any previously treated advanced (metastatic or refractory) solid
                  tumor

          -  For Cohort Expansion:

               -  Subjects must have a previously treated advanced solid tumor to be eligible

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Willing and able to provide pre-treatment and on-treatment fresh tumor biopsy

          -  Women of child-bearing potential and men must use an acceptable method of
             contraception during treatment and for 23 weeks after treatment for women and 31 weeks
             for men</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Known central nervous system metastases or central nervous system as the only source
             of disease

          -  Other concomitant malignancies (with some exceptions per protocol)

          -  Active, known or suspected autoimmune disease

          -  Uncontrolled or significant cardiovascular disease

          -  History of active or chronic hepatitis (e.g. Hep B or C)

          -  Impaired liver or bone marrow function

          -  Major surgery less than 1 month before start of the study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>9/10/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>310</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/02/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,WA</recruitmentstate>
    <hospital>Local Institution - Liverpool</hospital>
    <hospital>Local Institution - Westmead</hospital>
    <hospital>Princess Alexandra Hospital - Brisbane</hospital>
    <hospital>Local Institution - Nedlands</hospital>
    <postcode>2170 - Liverpool</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>4102 - Brisbane</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 5</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse Cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vlllejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Wuerzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>St. Gallen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zurich</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the safety and tumor-shrinking ability of
      experimental medication BMS-986156, when given by itself or in combination with nivolumab in
      patients with solid cancers that are advanced or cancers that have spread.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02598960</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</name>
      <address />
      <phone />
      <fax />
      <email>Clinical.Trials@bms.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>